Panixine DisperDose

Generic name:

Pantoprazole sodium

Drug class:

Proton pump inhibitors (PPIs)

Dosage form:

• Oral dispersible tablets: 20 mg, 40 mg

Root of administration:

Oral

Dose:

• 20 mg once daily for relief of heartburn and GERD symptoms
• 40 mg once daily for erosive esophagitis (4–8 weeks)
• Maintenance: 20 mg once daily
• Zollinger‐Ellison syndrome: 40–240 mg daily divided BID, adjust per response
• H. pylori eradication: 40 mg BID as part of combination therapy

Mechanism of action:

Pantoprazole is a substituted benzimidazole that irreversibly inhibits the H⁺/K⁺ ATPase enzyme system (proton pump) in gastric parietal cells, suppressing gastric acid secretion.

Drug usage cases:

• Gastroesophageal reflux disease (GERD)
• Erosive esophagitis
• Peptic ulcer disease (gastric and duodenal ulcers)
• H. pylori eradication in combination therapy
• Zollinger‐Ellison syndrome and other hypersecretory conditions
• NSAID‐associated ulcer prevention
• Off‐label: stress ulcer prophylaxis, laryngopharyngeal reflux

Drug contra indications:

• Hypersensitivity to pantoprazole or any PPI
• Concurrent use with rilpivirine‐containing products
• Severe hepatic impairment without close monitoring

Side effects:

• Common: headache, diarrhea, abdominal pain, nausea, flatulence, constipation, dizziness
• Dermatologic: rash, pruritus
• Laboratory: elevated liver enzymes, hypomagnesemia (with long‐term use)
• Serious: Clostridioides difficile–associated diarrhea, acute interstitial nephritis, vitamin B₁₂ deficiency, bone fracture risk, severe cutaneous adverse reactions (SJS/TEN), agranulocytosis

Warnings:

• Risk of fractures with long‐term high‐dose therapy
• Hypomagnesemia—monitor levels in prolonged use or with diuretics
• Clostridioides difficile infection—use lowest effective dose and shortest duration
• Acute interstitial nephritis—monitor renal function
• Lupus erythematosus‐like syndrome
• Cutaneous and systemic lupus erythematosus may develop or worsen
• Hepatic encephalopathy risk in cirrhotic patients—use with caution

Use during pregnancy or breastfeeding:

Pantoprazole is categorized as pregnancy category B. Animal studies have not demonstrated fetal risk, but adequate human studies are lacking. Use only if clearly needed. Pantoprazole is excreted in breast milk; monitor infants for gastrointestinal disturbances. Consider alternative therapies with more established safety profiles during lactation.